Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Download PDF
Thromb Haemost 1999; 82(06): 1703-1708
DOI: 10.1055/s-0037-1614902
DOI: 10.1055/s-0037-1614902
Rapid Communication
Factor XI Dependent and Independent Activation of Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in Plasma Associated with Clot Formation
Further Information
Publication History
Received
29 April 1999
Accepted after revision
08 July 1999
Publication Date:
10 December 2017 (online)
Summary
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) also known as plasma procarboxypeptidase B is activated by relatively high concentrations of thrombin in a reaction stimulated by thrombomodulin. In plasma an intact factor XI-dependent feed back loop via the intrinsic pathway is necessary to generate sufficient thrombin for TAFI activation. This thrombin generation takes place after clot formation with consequent down-regulation of fibrinolysis. We developed a specific and sensitive assay for activated TAFI (TAFIa) and studied its factor XI-dependent generation during clot formation. In the absence of thrombomodulin, addition of 20 nM thrombin to normal plasma generated 5-10% of the amount of TAFIa generated by 20 nM thrombin in the presence of 8 nM thrombomodulin. Minimal activation of TAFI was detected in factor II deficient plasma when clotting was initiated by 20 nM thrombin. Addition of 320-640 nM of thrombin to factor II deficient plasma resulted in the same amount of TAFIa as in normal plasma, suggesting that ~50% of factor II has to be converted to thrombin for extensive activation of TAFI. A Mab that neutralizes activated factor XII had no effect on TAFI activation indicating that an intact contact system is not necessary for the activation of TAFI. The dependency of TAFI activation of factor XI was tested using a Mab that neutralizes activated factor XI. When plasmas from 13 healthy individuals were tested, this Mab reduced TAFI activation by 65% (range 35-89%). Our results indicate that activation of TAFI in serum after clot formation can be quantitated and that it takes place in both factor XI-dependent and factor XI-independent mechanisms.
* JCMM is an Established Investigator of the Netherlands Heart Foundation (Grant D96.021). Supported in part by NIH grant HL 21544 and grant 96.088 from the Netherlands Heart Foundation.
-
References
- 1 Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
- 2 Comp PC, Esmon CT. Generation of fibrinolytic activity by infusion of activated protein C into dogs. J Clin Invest 1981; 68: 1221-8.
- 3 Sakata Y, Loskutoff DJ, Gladson CL, Hekman CM, Griffin JH. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 86: 1218-23.
- 4 Sakata Y, Curriden S, Lawrence D, Griffin JH, Loskutoff DJ. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity. Proc Natl Acad Sci USA 1985; 82: 1121-5.
- 5 van Hinsbergh VW, Bertina RM, van Wijngaarden A, van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-51.
- 6 de Fouw NJ, Haverkate F, Bertina RM. Protein C and fibrinolysis: a link between coagulation and fibrinolysis. Adv Exp Med Biol. 1990; 281: 235-43.
- 7 Bajzar L, Fredenburgh JC, Nesheim ME. The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system. J Biol Chem 1990; 265: 16948-54.
- 8 Bajzar L, Nesheim ME. The effect of activated protein C on fibrinolysis in cell free plasma can be attributed specifically to attenuation of prothrombin activation. J Biol Chem 1993; 268: 8608-16.
- 9 Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
- 10 Wang W, Hendriks DF, Scharpé SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
- 11 Nesheim M, Wang W, Boffa M, Nagashima M, Morser J, Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 1997; 78: 386-91.
- 12 Bajzar L, Morser J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
- 13 Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-6.
- 14 Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-8.
- 15 Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
- 16 Hendriks D, Scharpe S, van Sande M, Lommaert MP. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27: 277-85.
- 17 Von dem Borne PAKr, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
- 18 Von dem Borne PAKr, Bajzar L, Meijers JCM, Nesheim ME, Bouma BN. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-7.
- 19 Minnema MC, Friederich PW, Levi M, von dem Borne PAKr, Mosnier LO, Meijers JCM, Biemond BJ, Hack CE, Bouma BN, ten Cate H. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Invest 1998; 101: 10-4.
- 20 Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M. Activated protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein C reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest 1998; 101: 667-76.
- 21 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-8.
- 22 Gailani D, Broze GJ. Factor XI activation in a revised model of coagulation. Science 1991; 253: 909-12.
- 23 Von dem Borne PAKr, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent factor XI activation by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 1994; 72: 397-402.
- 24 Minnema MC, Pajkrt D, Wuillemin WA, Roem D, Bleeker WK, Levi M, van Deventer SJH, Hack CE, ten Cate H. Activation of clotting factor XI without detectable contact activation in experimental human endotoxemia. Blood 1998; 92: 3294-3301.
- 25 Von dem Borne PAKr, Mosnier LO, Tans G, Meijers JCM, Bouma BN. Factor XI activation by meizothrombin: stimulation by phospholipids vesicles containing both phosphatidylserine and phosphatidylethanolamine. Thromb Haemost 1997; 78: 834-9.
- 26 Oliver JA, Monroe DM, Roberts HR, Hoffman M. Thrombin activates factor XI on activated platelets in the absence of factor XII. Arterioscler Thromb Vasc Biol 1999; 19: 170-7.
- 27 Gailani D, Broze GJ. Factor XII-independent activation of factor XI in plasma: effects of sulfatides on tissue factor-induced coagulation. Blood 1993; 82: 813-9.
- 28 Lawson JH, Kalafatis M, Stram S, Mann KG. A model for the tissue factor pathway to thrombin. An empirical study. J Biol Chem 1994; 269: 23357-66.
- 29 Mosnier LO, von dem Borne PAKr, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
- 30 Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
- 31 Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-35.
- 32 Nesheim ME, Boffa MB, Wang W. The effects of temperature, GEMSA and EACA on the stability of activated TAFI. Fibrinolysis 1996; 10: 126 (Abstract).
- 33 Wang W, Boffa MB, Walker J, Nesheim ME. Reciprocal inactivation of TAFIa and plasmin. Fibrinolysis 1996; 10: 124 (Abstract).
- 34 Meijers JCM. Regulation of the blood coagulation mechanism by plasma proteinase inhibitors. Ph D Thesis State University of Utrecht; 1988: 93-108.
- 35 Hurst PL, Lovell Smith CJ. An optimized assay for serum angiotensin-converting enzyme. Clin Chem 1981; 27: 2048-52.
- 36 Hayakari M, Kondo Y, Izumi H. A rapid and simple spectrophotometric assay of angiotensin-converting enzyme. Anal Biochem 1970; 84: 361-9.
- 37 Suzuki S, Hachimori Y, Yaoeda U. Spectrophotometric determination of glycine with 2,4,6-trichloro-s-triazine. Anal Chem 1970; 42: 101-3.
- 38 Hendriks D, van Sande M, Scharpé S. Colorimetric assay for carboxypeptidase N in serum. Clin Chim Acta 1986; 157: 103-8.
- 39 Kessels H, Beguin S, Andree H, Hemker HC. Measurement of thrombin generation in whole blood – the effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
- 40 Weitz JI, Hudoba D, Massel J, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 386-91.
- 41 Kumar R, Beguin S, Hemker HC. The influence of fibrinogen on thrombin generation: evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-21.
- 42 Von dem Borne PAKr, Meijers JCM, Bouma BN. Effect of heparin on the activation of factor XI by fibrin bound thrombin. Thromb Haemost 1996; 76: 347-53.
- 43 Biemond BJ, Friederich PW, Levi M, Vlasuk GP, Büller HR, ten Cate JW. Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis. Circulation 1996; 93: 153-60.
- 44 Braat EAM, Los P, Rijken DC. The inactivation of single-chain urokinase-type plasminogen activator by thrombin in a plasma milieu: the effect of thrombomodulin. Blood Coag Fibrinol 1998; 9: 419-27.
- 45 Braat EAM, Rijken DC. The inactivation of single-chain urokinase type-plasminogen activator by thrombin may provide an additional explanation for the antifibrinolytic effect of factor XI. Thromb Haemost 1999; 81: 657.
- 46 Bouma BN, von dem Borne PAKr, Meijers JCM. Factor XI and protection of the fibrin clot against lysis - a role for the intrinsic pathway of coagulation in fibrinolysis. Thromb Haemost 1998; 80: 24-7.
- 47 Asakai R, Chung DW, Davie EW, Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. New Engl J Med 1991; 325: 153-8.
- 48 Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery in patients with severe factor XI deficiency without plasma replacement. Blood Coagul Fibrinol 1991; 3: 465-8.
- 49 Hsu TC, Shore SK, Seshsmma T, Bagasra O, Walsh PN. Molecular cloning of platelet factor XI, an alternative splice product of the plasma factor XI gene. J Biol Chem 1998; 273: 13787-93.
- 50 Hu CJ, Baglia FA, Mills DC, Konkle BA, Walsh PN. Tissue-specific expression of functional platelet factor XI is independent of plasma factor XI expression. Blood 1998; 91: 3800-7.